Pediatric expert consensus on the application of aspirin in Kawasaki disease.
10.7499/j.issn.1008-8830.2203190
- Collective Name:Shaanxi Province Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital;Children's Hospital of Shanghai Jiao Tong University;Beijing Children's Hospital of Capital Medical University;Shengjing Hospital of China Medical University;Affiliated Hospital of Yan'an University;Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association;General Pediatric Group of Pediatrician Branch of Chinese Medical Doctor Association;Shanghai Cooperation Organization Hospital Cooperation Alliance;Pediatric International Exchange and Cooperation Center;Editorial Board of Chinese Journal of Contemporary Pediatrics
- Publication Type:Journal Article
- Keywords:
Aspirin;
Child;
Expert consensus;
Kawasaki disease
- MeSH:
Aspirin/therapeutic use*;
Child;
Consensus;
Coronary Vessels/pathology*;
Humans;
Immunoglobulins, Intravenous/therapeutic use*;
Mucocutaneous Lymph Node Syndrome/pathology*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(6):597-603
- CountryChina
- Language:Chinese
-
Abstract:
Kawasaki disease (KD) is one of the common acquired heart diseases in children aged <5 years and is an acute systemic vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for the prevention of coronary artery lesion in acute KD; however, there are still controversies over the role and optimal dose of aspirin. The consensus was formulated based on the latest research findings of KD treatment in China and overseas and comprehensive discussion of pediatric experts in China and put forward recommendations on the dose, usage, and course of aspirin treatment in the first-line treatment of KD.
